Broker tips: Smith & Nephew, Resolution, Compass
28th Nov 2012 11:14
Investec has kept its 'hold' rating and 670p target price for medical technology group Smith & Nephew following Wednesday's proposed acquisition of Healthpoint Biotherapeutics. The broker said that the purchase is a "good fit" but raises the risk profile of the company as a whole. "For us, whilst t
Read moreBroker snap: S&N acquisition increases risk profile, says Investec
28th Nov 2012 11:13
Investec has kept its 'hold' rating and 670p target price for medical technology group Smith & Nephew following Wednesday's proposed acquisition of Healthpoint Biotherapeutics. Healthpoint, which will be acquired for $782m in cash, is a US-based leader in bioactive debridement, dermal repair and re
Read moreLondon open: Stocks fall as focus turns to 'fiscal cliff'
28th Nov 2012 08:31
UK stocks slipped in early trading on Wednesday, tracking US markets lower, as focus turned to the impending US 'fiscal cliff'. "European equities are trading lower this morning being pressured by a late sell-off in the US yesterday evening on fears that so far there has been too little progress be
Read moreLondon pre-open: FTSE set to erase Tuesday's gains
28th Nov 2012 07:26
City sources predict the FTSE 100 will open down 15 points from yesterday's close of 5,800, as concerns over the situation overtakes the confidence which followed the Greek bail-out agreement. The predicted losses will erase all of Tuesday's gains which resulted from the deal. The main US equity
Read moreSmith & Nephew strengthens wound care division with US acquisition - UPDATE
28th Nov 2012 07:06
Medical technology giant Smith & Nephew is to buy the assets of Healthpoint Biotherapeutics in an attempt to bolster its position in advanced wound care. Healthpoint, which will be acquired for $782m in cash, is a US-based leader in bioactive debridement, dermal repair and regeneration wound care t
Read moreSmith & Nephew plucks its new CFO from AstraZeneca
19th Nov 2012 13:24
Global medical technology business Smith & Nephew has appointed a director at AstraZeneca as its new Chief Financial Officer (CFO) to replace Adrian Hennah when he leaves at the end of December. Julie Brown, who has worked for AstraZeneca for 25 years, will formally takeover the role in early Febr
Read moreFTSE 100 movers: Lloyds reports progress and pleases investors
1st Nov 2012 15:32
Banking giant Lloyds rose strongly after an 'in-line' third-quarter statement. The lender said that it is making progress despite delivering a statutory loss before tax of £583m for the first nine months of the year, including a further Payment Protection Insurance (PPI) provision of £1bn in the thi
Read moreSmith & Nephew hobbled by Europe
1st Nov 2012 14:12
Global medical technology business Smith & Nephew experienced hard times in Europe in the third quarter and expects these to continue. Revenue in the three months to September 29th was up an underlying 1% but down an actual 7.8% at $952m from $1,032m the year before. Profit before tax eased to $188
Read moreMonday broker round-up
29th Oct 2012 08:10
African Barrick Gold: HSBC cuts target from 710p to 670p, overweight rating kept. African Eagle Resources: Seymour Pierce keeps buy rating. Anglo American: Nomura cuts target from 2,100p to 2,000p, neutral rating kept; UBS ups target from 2,230p to 2,250p, buy rating kept. Burberry: Goldman Sachs
Read moreWeek ahead: Banking results and election fever to take centre-stage
26th Oct 2012 09:08
Next week is set to be an extremely busy week, looking at the corporate and economic calendar from home and abroad. Third-quarter UK corporate earnings season really gets into full swing with some heavyweight Footsie constituents scheduled to report, including GlaxoSmithKline, Shell, Smith & Nephew
Read moreFTSE 100 movers: Burberry rises on signs of improved trading
11th Oct 2012 15:35
Shares in stock market darling Burberry, the luxury fashion chain, leapt on Thursday, after it said its situation had started to improve towards the end of the July-September quarter, during which time sales growth in its stores slowed dramatically, as expected. LFL sales over the half-year were u
Read moreLondon midday: Banking stocks gain, yet Footsie falls
10th Oct 2012 11:32
- IMF warns about Eurozone crisis - Unions call for strikes in Greece - Banks gain on speculation of eased capital rules UK stocks suffered more losses on Wednesday in spite of some relative strength in the banking sector, as the International Monetary Fund (IMF) warned about the risks emanating f
Read moreLondon open: Stocks fall on growth concerns again
10th Oct 2012 08:45
- Growth concerns take down stocks again - Alcoa trims demand forecast - Banks could need to shrink assets, says IMF The FTSE 100 was heading for its third consecutive day in the red, starting Wednesday's session on the back foot with global growth concerns continuing to weigh on sentiment. Trader
Read moreWednesday broker round-up - UDPATE
10th Oct 2012 08:22
African Barrick Gold: Nomura cuts target from 670p to 605p, buy rating kept. APR Energy: JPMorgan Cazenove initiates coverage with overweight rating and 1,005p target. ARM Holdings: Credit Suisse initiates coverage at neutral. ASOS: Seymour Pierce keeps hold rating and 1,900p target. Avanti Com
Read moreWednesday broker round-up - UPDATE
3rd Oct 2012 09:06
African Barrick Gold: Westhouse Secuirites raises target from 464p to 495p. AG Barr: Panmure Gordon keeps hold rating and 440p target. AstraZeneca: Panmure Gordon downgrades from buy to hold, target cut from 3,100p to 3,000p. Barclays: UBS downgrades from buy to neutral, 235p target unchanged. B
Read more